Clinical Trial

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This trial evaluated the efficacy of two adjuvant regimens following identical induction and concurrent chemoradiotherapy (IC+CCRT) in locoregionally advanced nasopharyngeal carcinoma (LANPC) patients with persistent EBV DNA positivity or stable disease after three IC cycles. The control arm received adjuvant adebrelimab, while the experimental arm received adebrelimab plus capecitabine.
Trial Details
NCT Number NCT07238569
Lead Sponsor Sun Yat-sen University
Conditions Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
Enrollment 516 participants
Start Date 2025-12-01
Primary Completion 2029-12-01 (estimated)
Study Completion 2031-05-23 (estimated)
Updated on ClinicalTrials.gov 2025-11-20